Ownership history in ALLIANCEBERNSTEIN L.P. Β· 3 quarters on record
This page tracks every 13F SEC filing in which ALLIANCEBERNSTEIN L.P. reported a position in GYRE THERAPEUTICS INC (GYRE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π ALLIANCEBERNSTEIN L.P. underperformed the S&P 500 by β29.3% annually on this GYRE position. Average cost basis: $7.36. Maximum drawdown during holding period: β5.4%.
β Significantly underperformed the S&P 500 by 29.3% ann.
2 quarters analyzed
Best entry: $7.35 (2025 Q2) Β· Worst: $7.46 (2025 Q3)
π No drawdown exceeding 20% during the holding period β exceptionally stable.
2 adds Β· 0 trims. Bought during 0 of 1 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size